UK-headquartered EUSA Pharma has filed a marketing application for kidney cancer drug tivozanib with the European Medicines Agency.
The company is seeking permission to market the drug – to which it licensed certain rights from US group AVEO Oncology late last year – for the first-line treatment of advanced renal cell carcinoma (RCC).
Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor being assessed across multiple tumour types.
According to the firm, it is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimise VEGF blockade while minimising toxicity to healthy tissues, “potentially resulting in improved efficacy and minimal dose modifications”.
Under the companies’ license agreement, EUSA holds exclusive commercialisation rights to tivozanib in RCC in Europe and in a number of other territories outside North America, including South America and South Africa, in addition to a range of further indications.
EUSA Pharma will undertake and fund the commercialisation of the product in its territories, assuming approval.
